2024 Revenue Guidance: Raised to $16.1 billion to $16.5 billion. 2024 EPS Guidance: Raised to $2.40 to $2.50. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 15% increase in revenues, ...

DelveInsight’s “Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

On October 31, 2024, the European Commission (EC) fined Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva) ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited earnings conference call. My name is Alex, ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance after beating third-quarter profit forecasts, ...

Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...

Leading pharmaceutical companies, such as Teva and Siemens Healthineers, reported significant profit growth, leading to ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.